

Esquizofrènia i altres trastorns psicòtics

Producció científica 2009

Alonso J, Buron A, Rojas S, De Graaf R, Haro JM, De Girolamo G, Bruffaerts R, Kovess V, Matschinger H, Vilagut G. ESEMed/MHEDEA 2000 investigators. Perceived stigma among individuals with common mental disorders. *J Affect Disord* **2009** ; 118 (1-3) : 180-6

Factor impacte: 3,271

Arranz B, San L, Ramírez N, Dueñas RM, Perez V, Salavert J, Corripio I, Alvarez E. Clinical and serotonergic predictors of non-affective acute remitting psychosis in patients with a first-episode psychosis. *Acta Psychiatr Scand* **2009** ; 119 (1) : 71-7

Factor impacte: 3,525

Arranz B, Brevion G, Haro JM, Ochoa S, Ramos B, San L, Stephanotto C. The Saint John of God Mental Health Research group in Barcelona. *Eur J Psychiatry* **2009** ; 23 (supl.) : 70-5

Azorin JM, Aubrun E, Bertsch J, Reed C, Gerard S, Lukasiewicz M. Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication. *BMC Psychiatry* **2009** ; 9 : 33

Bernert S, Matschinger H, Alonso J, Haro JM, Brugha TS, Angermeyer MC. ESEMed/MHEDEA 2000 investigators. Is it always the same? Variability of depressive symptoms across six European countries. *Psychiatry Res* **2009** ; 168 (2) : 137-44

Factor impacte: 2,666

Bobes J, Ciudad A, Alvarez E, San L, Polavieja P, Gilaberte I. Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. *Schizophr Res* **2009** ; 115 (1) : 58-66

Factor impacte: 4,174

Bonnewyn A, Katona C, Bruffaerts R, Haro JM, De Graaf R, Alonso J, Demyttenaere K. Pain and depression in older people: comorbidity and patterns of help seeking. *J Affect Disord* **2009** ; 117 (3) : 193-6

Factor impacte: 3,271

Brébion G, Bressan RA, Pilowsky LS, David AS. Depression, avolition, and attention disorders in patients with schizophrenia: associations with verbal memory efficiency. *J Neuropsychiatry Clin Neurosci* **2009** ; 21 (2) : 206-15

Factor impacte: 2,362

Brébion G, David AS, Bressan RA, Ohlsen RI, Pilowsky LS. Hallucinations and two types of free-recall intrusion in schizophrenia. *Psychol Med* **2009** ; 39 (6) : 917-26

Factor impacte: 4,718

Brébion G, Bressan RA, David AS, Pilowsky LS. Role of processing speed and premorbid IQ on visual recognition in patients with schizophrenia. *J Clin Exp Neuropsychol* **2009** ; 31 (3) : 302-11

Factor impacte: 2,184

Brébion G, David AS, Jones HM, Pilowsky LS. Working memory span and motor and cognitive speed in schizophrenia. *Cogn Behav Neurol* **2009** ; 22 (2) : 101-8

Factor impacte: 1,882

Carlson J, Ochoa S, Haro JM, Escartin G, Ahuir M, Gutierrez-Zotes A, Salamero M, Valero J, Cañizares S, Bernardo M, Cañete J, Gallo P. Adaptation and validation of the quality-of-life scale: Satisfaction with Life Domains Scale by Baker and Intagliata. *Compr Psychiatry* **2009** ; 50 (1) : 76-80

Factor impacte: 2,054

Catafau AM, Suarez M, Bullich S, Llop J, Nucci G, Gunn RN, Brittain C, Laruelle M. Within-subject comparison of striatal D2 receptor occupancy measurements using [¹²³I]BZM SPECT and [¹¹C]Raclopride PET. *Neuroimage* **2009** ; 46 (2) : 447-58

Factor impacte: 5,694

Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte I. Remission in schizophrenia: results from a 1-year follow-up observational study. *Schizophr Res* **2009** ; 108 (1-3) : 214-22

Factor impacte: 4,174

Codony M, Alonso J, Almansa J, Bernert S, De Girolamo G, De Graaf R, Haro JM, Kovess V, Vilagut G, Kessler RC. Perceived need for mental health care and service use among adults in Western Europe: results of the ESEMeD project. *Psychiatr Serv* **2009** ; 60 (8) : 1051-8

Factor impacte: 2,481

Coromina Sadurni M, Usall J, de Montagut LM, Sánchez Autet M. The Use of oral contraceptives as a prevention of recurrent premenstrual psychosis. *Psychiatry Res* **2009** ; 170 (2-3) : 290-1

Factor impacte: 2,666

Escuder G, Gomollón LG, Vicens E. Delitos violentos y trastorno mental en la unidad de hospitalización psiquiátrica penitenciaria de Catalunya. *An Psiquiatr* **2009** ; 25 (3) : 125-132

Fusco F, Sicuteri R, Rossi A, Kontodimas S, Haro JM, Imbimbo C, Mireno V. Italian EDOS Study Group. Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. *Asian J Androl* **2009** ; 11 (5) : 629-37

Factor impacte: 2,059

Gándara de la, San L, Rodríguez A, Hidalgo R, Burón JA. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. *Expert Rev Neurother* **2009** ; 9 (10) : 1463-74

Gonzalez Pinto A, Mosquera F, Reed C, Novick D, Barbeito S, Vega P, Bertsch J, Alberich S, Haro JM. Validity and reliability of the Hamilton depression rating scale (5 items) for manic and mixed bipolar disorders. *J Nerv Ment Dis* **2009** ; 197 (9) : 682-6

Factor impacte: 1,810

Haro JM, Novick D, Suárez D, Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. *J Psychiatr Res* **2009** ; 43 (3) : 265-73

Factor impacte: 4,679

Hong J, Windmeijer F, Novick D, Haro JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. *Prog Neuropsychopharmacol Biol Psychiatry* **2009** ; 33 (5) : 835-41

Factor impacte: 2,638

Karagianis J, Novick D, Pecenak J, Haro JM, Dossenbach M, Treuer T, Montgomery W, Walton R, Lowry AJ. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients* *Int J Clin Pract* **2009** ; 63 (11) : 1578-88

Factor impacte: 2,007

König HH, Bernert S, Angermeyer MC, Matschinger H, Martinez M, Vilagut G, Haro JM, Girolamo GD, Graaf R de, Kovess V, Alonso J. ESEMed/MHEDEA 2000 investigators. Comparison of population health status in six european countries: results of a representative survey using the EQ-5D Questionnaire. *Med Care* **2009** ; 47 (2) : 255-61

Factor impacte: 3,194

Lara C, Fayyad J, Graaf RD, Kessler RC, Aguilar Gaxiola S, Angermeyer MC, Demyttenaere K, Girolamo GD, Haro JM, Jin R, Karam EG, Lepine JP, MoraME, Ormel J, Posada Villa J, Sampson N. Childhood Predictors of Adult Attention-Deficit/Hyperactivity Disorder: Results from the World Health Organization World Mental Health Survey Initiative. *Biol Psychiatr* **2009** ; 65 (1) : 46-54

Factor impacte: 8,672

Lee S, Tsang A, von Korff M, De Graaf R, Benjet C, Haro JM, Angermeyer MC, Demyttenaere K, De Girolamo G, Gasquet I, Merikangas KR, Posada Villa J, Takeshima T, Kessler RC. Association of headache with childhood adversity and mental disorder: cross-national study. *Br J Psychiatry* **2009** ; 194 (2) : 111-6

Factor impacte: 5,077

Lee S, Tsang A, Breslau J, Aguilar Gaxiola S, Angermeyer MC, Borges G, Bromet EJ, Bruffaerts R, De Girolamo G, Fayyad J, Gureje O, Haro JM, Kawakami N, Levinson D, Oakley MA, Ormel J, Posada Villa J, Williams DR, Kessler RC. Mental disorders and termination of education in high-income and low- and middle-income countries: epidemiological study. *Br J Psychiatry* **2009** ; 194 (5) : 411-7

Factor impacte: 5,077

Montoya A, Hong J, Carlson J, Asensio F, Marques-Teixeira J, Alda JA, Gaudillière B, Garrido M, Gilaberte I, Escuder G. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder. *Curr Med Res Opin* **2009** ; 25 (11) : 2745-54

Factor impacte: 2,596

Nock MK, Hwang I, Sampson N, Kessler RC, Angermeyer MC, Beautrais A, Borges G, Bromet EJ, Bruffaerts R, De Girolamo G, De Graaf R, Florescu S, Gureje O, Haro JM, Hu C, Huang Y, Karam EG, Kawakami N, Kovess V, Levinson D, Posada Villa J, Sagar R, Tomov T, Viana MC, Williams DR. Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys. *PloS Med* **2009** ; 6 (8) : e1000123

Factor impacte: 12,185

Novick D, Haro JM, Suárez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. *Schizophr Res* **2009** ; 108 (1-3) : 223-30

Factor impacte: 4,174

Novick D, Haro JM, Perrin E, Suárez D, Teixeira JM. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. *Eur Neuropsychopharmacol* **2009** ; 19 (8) : 542-50

Factor impacte: 3,661

Novick D, Gonzalez Pinto A, Haro JM, Bertsch J, Reed C, Perrin E, Tohen M. Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. *Pharmacopsychiatry* **2009** ; 42 (4) : 145-52

Factor impacte: 2,402

Ochoa S, Vilaplana M. Abordaje familiar de las personas con esquizofrenia. *Jano* **2009** (1278) : 23-5

Portugal E de, González N, Vilaplana M, Haro JM, Usall J, Cervilla JA. Un Estudio empírico de los correlatos psicosociales y clínicos del trastorno delirante: el estudio DELIREMP. *Rev Psiquiatr Salud Mental* **2009** ; 2 (2) : 72-82

Ramos B, Valin A, Sun X, Gill G. Sp4-dependent repression of Neurotrophin-3 limits dendritic branching. *Mol Cell Neurosci* **2009** ; 42 (2) : 152-9

Factor impacte: 3,934

Reed C, Novick D, Gonzalez Pinto A, Bertsch J, Haro JM. Observational study designs for bipolar disorder. What can they tell us about treatment in acute mania? *Prog Neuropsychopharmacol Biol Psychiatry* **2009** ; 33 (4) : 715-21

Factor impacte: 2,638

Salavert J, San L, Arranz B, Ramírez N, Sintés A. Trastornos de la personalidad del grupo B y trastorno por uso de sustancias: tipos de tratamientos y dispositivos terapéuticos. *Aula Médica Psiquiatría* **2009** ; 11 (1) : 29-51

San L, Arranz B, Ramírez N, Salavert J. Esquizofrenia y trastorno por uso de sustancias: clínica, diagnóstico y tratamiento. *Aula Médica Psiquiatría* **2009** ; 11 (1) : 3-13

San L, Arranz B, Moral E del. Trastorno bipolar y trastorno por uso de sustancias. *Aula Médica Psiquiatría* **2009** ; 11 (1) : 15-28

San L, Arranz B. Tratamiento de la patología dual. *Aula Médica Psiquiatría* **2009** ; 11 (1) : 1-2

Scott KM, von Korff M, Alonso J, Angermeyer MC, Bromet EJ, Fayyad J, De Girolamo G, Demyttenaere K, Gasquet I, Gureje O, Haro JM, He Y, Kessler RC, Levinson D, Medina Mora ME, Oakley MA, Ormel J, Posada Villa J, Watanabe M, Williams D. Mental-physical co-morbidity and its relationship with disability: results from the World Mental Health Surveys. *Psychol Med* **2009** ; 39 (1) : 33-43

Factor impacte: 4,718

Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, Demyttenaere K, De Girolamo G, Haro JM, Jin R, Karam EG, Kovess V, Levinson D, Medina Mora ME, Ono Y, Ormel J, Pennell BE, Posada Villa J, Sampson NA, Williams D, Kessler RC. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. *Arch Gen Psychiatry* **2009** ; 66 (7) : 785-95

Factor impacte: 14,273

Suárez D, Haro JM, Novick D, Perrin E, Ochoa S, Naber D. Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia. *Pharmacopsychiatry* **2009** ; 42 (4) : 135-40

Factor impacte: 2,402

Tabarés R, Gómez Beneyto M, Haro JM, Gonzalez Pinto A, Vieta E. The Importance of negative comorbidity. *J Clin Psychiatry* **2009** ; 70 (8) : 1191-2

Factor impacte: 5,053

Usall J, Pinto Meza A, Fernández A, Graaf RD, Demyttenaere K, Alonso J, Girolamo GD, Lepine JP, Kovess V, Haro JM. Suicide ideation across reproductive life cycle of women: results from a European epidemiological study. *J Affect Disord* **2009** ; 116 (1-2) : 144-7

Factor impacte: 3,271

Vieta E, Angst J, Reed C, Bertsch J, Haro JM. EMBLEM Advisory Board. Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM). *J Affect Disord* **2009** ; 118 (1-3) : 118-23

Factor impacte: 3,271

SUMATORI TOTAL FI: 144,913